EDAP to Present at the Jefferies Global Healthcare Conference
EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Ryan Rhodes will deliver a presentation and conduct one-on-one investor meetings during the conference, scheduled for June 3-5, 2025, in New York City.
Rhodes' presentation is set for Thursday, June 5th, from 4:20-4:50 PM ET. Investors can access both the live and archived webcast of the presentation through the company's website's Investor section or via the provided webcast link.
Details
News Market Reaction – EDAP
The recorded move for EDAP in the trading session of this news was -1.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.
Presentation details:
| Date: | Thursday, June 5th |
| Time: | 4:20-4:50 PM ET |
| Webcast: | https://wsw.com/webcast/jeff319/edap/1824368 |
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.